Recent Recurrent Bladder Cancer News

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer (March 30, 2015)

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented... Continue Reading

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer (March 16, 2015)

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment.... Continue Reading

Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer (June 23, 2014)

Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014... Continue Reading

Experimental Drug Shows Promise for Treatment of Metastatic Bladder Cancer (June 12, 2014)

According to results of a Phase I trial presented at the 2014 annual meeting of the American Society of Clinical Oncology, an investigative drug, MPDL3280A, demonstrates promise for the treatment of PD-L1... Continue Reading

Robotic Bladder Cancer Surgery Safe and Effective (January 24, 2013)

Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival... Continue Reading

Cystoscopy Alone Is the Most Cost-effective Way to Monitor for Recurrence of Bladder Cancer (March 9, 2010)

The addition of a urine test to standard cystoscopy screening in order to monitor for bladder cancer recurrence unnecessarily increases the cost of monitoring as well as the risk for a false-positive... Continue Reading